Vivos Q1 2025 product rev +8% YoY, net loss $3.9M; acquires Sleep Center of Nevada for up to $9M

Vivos Therapeutics, Inc.

2025-Q1 EPS reported -$0.45 vs consensus -$0.41 ▼ miss (-10.3%)

Revenue $3.0M (-12% YoY) as pivot away from VIP service revenue; product revenue up 8% to $1.8M from appliance arch sales.
Net loss $3.9M (+3% YoY); operating expenses $5.4M (-5% YoY) reflecting cost-cutting.
Cash $2.3M, equity $4.4M at March 31, 2025.
Entered definitive agreement on April 15, 2025 to acquire The Sleep Center of Nevada for up to $9M cash/stock; expected close within two months.
Sold 3,736 oral appliance arches (vs 1,996 in Q1 2024) driving product revenue increase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.